OTHER GROUP COMPANIES
market

Lupin receives USFDA approval for Meclizine Hydrochloride Tablets

Lupin receives USFDA approval for Meclizine Hydrochloride Tablets

August 12, 2022 3:43 IST | capital market
Lupin today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg, to market a generic equivalent of Antivert? Tablets, 12.5 mg, 25 mg, and 50 mg, of Casper Pharma LLC. The product will be manufactured at Lupins facility in Goa, India. Meclizine Hydrochloride Tablets (RLD Antivert?) had estimated annual sales of USD 29 million in the U.S. (IQVIA MAT June 2022).Powered by Capital Market - Live News

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account
  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity